We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+4.23%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$290M
AUM Growth
-$94.3M
Cap. Flow
-$85.7M
Cap. Flow %
-29.53%
Top 10 Hldgs %
69.05%
Holding
35
New
2
Increased
3
Reduced
20
Closed
6

Top Buys

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$6.45M
2
AXDX
Accelerate Diagnostics
AXDX
+$2.06M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$1.1M
4
FBIO icon
Fortress Biotech
FBIO
+$174K
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$46.5K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$19.2M
2
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$11.4M
3
VNDA icon
Vanda Pharmaceuticals
VNDA
+$8.62M
4
SRNE
Sorrento Therapeutics, Inc.
SRNE
+$8.48M
5
SPPI
Spectrum Pharmaceuticals Inc
SPPI
+$7.87M

Sector Composition

Rank Sector Weight
1 Healthcare 90.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$39.8M 13.69%
1,258,055
-195,000
-13% -$6.89M
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$34.1M 11.75%
3,515,611
-734,588
-17% -$6.62M
IOVA icon
3
Iovance Biotherapeutics
IOVA
$2.04B
$24.6M 8.48%
3,187,607
+6,694
+0.2% +$46.5K
LJPC
4
DELISTED
La Jolla Pharmaceutical Company
LJPC
$21.2M 7.29%
784,199
-20,100
-2% -$548K
SRPT icon
5
Sarepta Therapeutics
SRPT
$1.64B
$19.4M 6.68%
503,007
+33,982
+7% +$1.1M
PTX
6
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
$15.2M 5.23%
514,492
-85,964
-14% -$2.6M
DERM
7
DELISTED
Dermira, Inc.
DERM
$12.3M 4.23%
354,950
-8,300
-2% -$238K
TLGT
8
DELISTED
Teligent, Inc
TLGT
$12.2M 4.21%
137,329
-40,649
-23% -$3.26M
VNDA icon
9
Vanda Pharmaceuticals
VNDA
$304M
$11.7M 4.04%
1,260,809
-863,784
-41% -$8.62M
SRNE
10
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$9.99M 3.44%
1,146,579
-1,004,858
-47% -$8.48M
AGEN
11
Agenus
AGEN
$276M
$9.98M 3.44%
112,046
– –
CASC
12
DELISTED
Cascadian Therapeutics, Inc.
CASC
$9.14M 3.15%
686,512
-231,258
-25% -$3.98M
NDRM
13
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$8.87M 3.05%
520,022
-583,071
-53% -$11.4M
IBRX icon
14
ImmunityBio
IBRX
$7.15B
$8.83M 3.04%
599,287
-129,600
-18% -$1.92M
AEGR
15
DELISTED
Aegerion Pharmaceuticals
AEGR
$7.41M 2.55%
733,125
-73,175
-9% -$881K
NBIX icon
16
Neurocrine Biosciences
NBIX
$18.2B
$7.18M 2.47%
+127,000
New +$6.45M
SIOX
17
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.54M 1.91%
38,384
-12,425
-24% -$1.62M
VCYT icon
18
Veracyte
VCYT
$4.45B
$5.34M 1.84%
741,353
-30,944
-4% -$208K
EGLT
19
DELISTED
Egalet Corporation
EGLT
$4.77M 1.64%
432,606
-8,000
-2% -$79.3K
INNL
20
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$4.16M 1.43%
501,722
-700
-0.1% -$7.01K
FBIO icon
21
Fortress Biotech
FBIO
$111M
$3.73M 1.29%
89,191
+4,156
+5% +$174K
TRIL
22
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.2M 1.1%
253,697
-1,400
-0.5% -$19.5K
VCEL icon
23
Vericel Corp
VCEL
$2.38B
$2.93M 1.01%
1,135,120
– –
TNXP icon
24
Tonix Pharmaceuticals
TNXP
$152M
– –
0
– –
AXDX
25
DELISTED
Accelerate Diagnostics
AXDX
$2.43M 0.84%
+11,289
New +$2.06M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Avoro Capital Advisors's Q4 2015 Portfolio in Review

As of Q4 2015, Avoro Capital Advisors held 35 positions worth $290M, down 25% from $385M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Avoro Capital Advisors withdrew a net $85.7M in Q4 2015, closing 6 positions and reducing 20 holdings. Its most notable exit was Acadia Pharmaceuticals, an estimated $19.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier.

Against the trend, Avoro Capital Advisors opened a new position in Neurocrine Biosciences worth $7.18M.

  • Avoro Capital Advisors's largest Q4 2015 buy was Neurocrine Biosciences: 127,000 shares worth $7.18M.
  • Avoro Capital Advisors added most to Sarepta Therapeutics in Q4 2015, an estimated $1.1M increase.
  • Avoro Capital Advisors's biggest Q4 2015 reduction was NeuroDerm Ltd. Ordinary Shares, cutting an estimated $11.4M.
  • Avoro Capital Advisors fully exited Acadia Pharmaceuticals in Q4 2015, selling an estimated $19.2M.
  • Avoro Capital Advisors's ten largest holdings make up 69% of its $290M portfolio in Q4 2015.
  • Avoro Capital Advisors opened 2 new positions and closed 6 in Q4 2015.
  • Avoro Capital Advisors's portfolio value fell 25% quarter-over-quarter to $290M.

Based on Avoro Capital Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.